CoChat

Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial

Open access
Krumholz, Harlan M, de Lemos, James A, Sattar, Naveed, Linetzky, Bruno, Sharma, Palash, Mast, Casey J, Ahmad, Nadia N, Bunck, Mathijs C, Stefanski, Adam · 2024 · Heart
Cited by 54

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background: Treating obesity may be a pathway to prevent and control hypertension. In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction. Post hoc analyses were conducted to further explore the effects of tirzepatide on the pattern of blood pressure reduction and whether the effects were consistent across various subgroups. Methods: The mixed effect for repeated measure model was used to compare changes in overall blood pressure, across demographic and clinical subgroups, baseline blood pressure subgroups and hypertension categories between SURMOUNT-1 participants randomised to treatment with tirzepatide and placebo. The association between weight changes and blood pressure and adverse events associated with low blood pressure were also evaluated by mediation analysis. Results: Tirzepatide treatment was associated with a rapid decline in systolic and diastolic blood pressure over the first 24 weeks, followed by blood pressure stabilisation until the end of the observation period, resulting in a significant net reduction by 72 weeks of 6.8 mm Hg systolic and 4.2 mm Hg diastolic blood pressure versus placebo. Participants randomly assigned to any tirzepatide group were more likely than those assigned to placebo to have normal blood pressure at week 72 (58.0% vs 35.2%, respectively). The effects were broadly consistent across baseline blood pressure subgroups, shifting the blood pressure distribution curve to lower blood pressure levels. The mediation analysis indicated that weight loss explained 68% of the systolic and 71% of the diastolic blood pressure reduction. Low blood pressure adverse events were infrequent, but the rate was higher in the tirzepatide group. Conclusions: In these post hoc analyses, in participants with obesity or overweight, tirzepatide was associated with reduced blood pressure consistently across participant groups primarily via weight loss, with relatively few blood pressure-related adverse events. Trial registration number: NCT04184622.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/heartjnl-2024-324170

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 8

  1. Muntner, 2020, Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018, JAMA, 324, 1190, 10.1001/jama.2020.14545 · DOI · Paper page
  2. 10.1016/j.jacc.2020.03.009 · DOI
  3. Leslie, 2021, Antihypertensive medication needs and blood pressure control with weight loss in the diabetes remission clinical trial (DiRECT), Diabetologia, 64, 1927, 10.1007/s00125-021-05471-x · DOI · Paper page
  4. Hall, 2021, Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association, Hypertension, 78, e38, 10.1161/HYP.0000000000000202 · DOI · Paper page
  5. Kennedy, 2023, The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis, J Clin Med, 12, 10.3390/jcm12030772 · DOI
  6. Costello, 2021, Circadian rhythm, clock genes, and hypertension: recent advances in hypertension, Hypertension, 78, 1185, 10.1161/HYPERTENSIONAHA.121.14519 · DOI
  7. 10.1136/heartjnl-2021-320171 · DOI
  8. 10.1016/S0140-6736(19)31149-3 · DOI · Paper page

Cited by

See all 54

Metadata

Authors
Krumholz, H. M., de Lemos, J. A., Sattar, N., Linetzky, B., Sharma, P., Mast, C. J., Ahmad, N. N., Bunck, M. C., & Stefanski, A.
Venue
Heart
Publisher
BMJ
Published
2024-07-31
Volume
110
Issue
19
Pages
1165-1171
ISSN
  • 1355-6037 (ISSN-L)
  • 1468-201X
OpenAlex
W4401168218
Cited by
54
References
12
FWCI
14.50
Type
journal article
Language
en
Open access
hybrid
Funders
Eli Lilly and Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. https://app.cochat.ai/papers/10.1136/heartjnl-2024-324170
The paper
Krumholz, H. M., de Lemos, J. A., Sattar, N., Linetzky, B., Sharma, P., Mast, C. J., Ahmad, N. N., Bunck, M. C., & Stefanski, A. (2024). Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart. https://doi.org/10.1136/heartjnl-2024-324170

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.